Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,466.05 -3.25 (-0.06%) Dow
38,954.96 -157.20 (-0.40%) Nasdaq
17,771.10 +53.44 (+0.30%) Bitcoin USD
61,847.12 +629.05 (+1.03%) CMC Crypto 200
1,280.20 -3.58 (-0.28%)
ITCI Jun 2024 45.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:58PM EDT. Market open.
| Previous close | 31.50 |
| Open | 31.40 |
| Bid | 29.00 |
| Ask | 31.60 |
| Strike | 45.00 |
| Expiry date | 2024-06-21 |
| Day's range | 31.40 - 31.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.